Category: Chronic Pulmonary Disorders

Chronic Pulmonary Disorders

Cystic Fibrosis Care Still Below Pre-Pandemic Levels

New data shows that patient visits and lung function tests for cystic fibrosis have not returned to 2019 levels despite new treatments and telehealth options.

Chronic Pulmonary Disorders

How Genetic Mutations Cause Primary Ciliary Dyskinesia

An imaging study reveals how gene mutations impair airway clearance and lead to primary ciliary dyskinesia (PCD).

Chronic Pulmonary Disorders

Combination CF Drugs Formoterol + Methacholine May Improve Mucus Clearance

Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.

Asthma

Tezepelumab Reduced Asthma Attacks

A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.

COPD

Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function

AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.

Cystic fibrosis

COVID-19 Outcomes in Cystic Fibrosis Transplant Patients

New research indicates that baseline lung health is a stronger predictor of SARS-CoV-2 outcomes in cystic fibrosis transplantation patients than the time elapsed since transplantation.

Pulmonary Fibrosis

Nebulized Treprostinil Preserved IPF Lung Function

Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).

Allergies

Fatal Pediatric Anaphylaxis Linked to Delays in Epinephrine Treatment

New studies suggest that airway and breathing failures are the primary causes of death in childhood food anaphylaxis, requiring a shift in emergency management protocols.

Other Chronic Diseases

Alpha-1 Drug Candidate Superior to Standard Care

Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.